



ADAMAS

ADAMAS CONSULTING

QUALITY INVESTIGATOR  
SITE ASSESSMENT  
(QISA)

# QUALITY INVESTIGATOR SITE ASSESSMENT

The COVID-19 pandemic and its effects on individuals, the health system, economy and nations has not been seen before. The repercussions on travel restrictions, access to hospitals and surgeries for monitoring and audit purposes are far reaching, and meeting Sponsor obligations towards clinical trial subjects and employees, represents a further challenge.

The potential risk of this global COVID-19 pandemic and the associated travel, access and resource restrictions include but are not limited to:

- **AN INCREASE IN THE NUMBER OF PROTOCOL DEVIATIONS**
- **RISE IN GOOD CLINICAL PRACTICE NON-COMPLIANCE**
- **INSUFFICIENT EVIDENCE OF SPONSOR AND INVESTIGATOR OVERSIGHT**
- **INVESTIGATIONAL MEDICINAL PRODUCT (IMP) SUPPLY, COMPLIANCE AND**
- **MANAGEMENT ISSUES**
- **INSUFFICIENT MANAGEMENT AND DOCUMENTATION OF SITE-SPECIFIC RISKS**



# ADAMAS'S QUEST

ADAMAS's goal is not only to provide quality assurance services by conducting high quality audits on behalf of Sponsor companies but also to add value and provide innovative solutions to ensure compliance with regulatory obligations for quality assurance and oversight, thereby ensuring that patient safety, data integrity and scientific validity are consistently maintained.

ADAMAS has developed an alternative to the traditional Investigator Site Audit (ISA) to enable Sponsors to continue to monitor compliance in these exceptional times. We refer to remote site audits as Quality Investigator Site Assessments (QISA) as some aspects of routine ISAs cannot be performed but, they do allow the highest possible degree of Sponsor Oversight and reassurance.

## CAPABILITIES OF QISAS

QISAs allow the evaluation of several key aspects of the traditional ISA:

- **KEY QUALITY STANDARDS OF SITES**
- **SITE MANAGEMENT AND MONITORING ACTIVITIES**
- **ESSENTIAL DOCUMENTS**
- **ETHICS AND REGULATORY COMPLIANCE**
- **SPONSOR AND PRINCIPAL INVESTIGATOR OVERSIGHT**
- **SUBJECT COMPLIANCE AND SAFETY BASED ON AVAILABLE ELECTRONIC DATA**

Advancements in available technology, the use of electronic Trial Master Files (eTMFs), document share options, and video conferencing provide the ideal platforms/tools for QISAs.



## ADVANTAGES OF QISAS

### ▪ REGULATORY COMPLIANCE

- QISAs contribute to the risk-based approach in site selection for ISAs, the outcome providing Sponsors with relevant insight in identifying investigational sites requiring a more detailed, on-site ISA focussing on key areas of concern identified during the QISA
- Demonstrates continued Sponsor oversight to regulatory authorities

### ▪ EXTENDED QUALITY ASSESSMENT

- QISAs can focus on individual or a series of investigator sites, for a specific programme simultaneously or consecutively, to facilitate the efficient identification of any systemic issues
- ADAMAS Insights© database can provide analysis on any high-risk findings to be used in determining whether the site should have an on-site audit, or provide an analysis on the whole programme to identify study-wide areas for improvement
- A review of outsourced activities can be included in the remote assessment, e.g. Project Management, Monitoring and Site Management on a Program Level, and Document Management
- Sponsor representatives may attend interviews and/or the opening and closing meeting, receiving first-hand and up to date information on the QISA's progress

- **COST EFFICIENCY**

- QISAs are more cost effective as travel and other associated expenses do not apply

- **FLEXIBILITY**

- Activities can be organised to accommodate all participants, minimise the disruption at investigator sites, and reduce the risk of time wastage (for example, waiting on interviewees, having to change audit location due to room availability etc)

- The Clinical Research Associate (CRA) can participate remotely, thus avoiding the cost of additional monitoring visits to site

- Anonymised data available on external databases, e.g. laboratory results, electronic Patient Reported Outcomes (ePRO), Central Reader vendors for images and electrocardiograms can be reviewed independently of the sites' availability

- **COMMUNICATION**

- The CRA or another member of the Clinical Operations team can assist with translations during interviews as they would during traditional ISAs

- Video conferencing systems are used to allow visual contact

- ADAMAS has an encrypted file sharing tool, Tresorit, which enables secure access to documents

# PREREQUISITES

- **ACCESS TO AVAILABLE SYSTEMS FOR REMOTE DOCUMENT REVIEW, INCLUDING BUT NOT LIMITED TO:**
  - eTMF or access to a document share platform
  - Electronic Case Report Forms (eCRFs)
  - Electronic Patient Reported Outcomes (ePRO)
  - Central reader vendor database and/or reporting systems
  
- **A SITE QUESTIONNAIRE MAY BE USED TO GATHER INFORMATION ABOUT THE SITE IN ADVANCE OF THE INTERVIEW SESSIONS, TO ALLOW SITE PERSONNEL TO PREPARE ANSWERS THAT MIGHT NOT BE IMMEDIATELY AVAILABLE AND HELP TO FOCUS INTERVIEW QUESTIONS AS WELL AS DOCUMENT REVIEW. TOPICS OF THE QUESTIONNAIRE MIGHT INCLUDE BUT ARE NOT LIMITED TO:**
  - Facility and equipment used
  - Known issues
  - Source data generation including 21 CFR Part 11 compliance if Electronic Medical record systems are used

PLEASE GET IN TOUCH TODAY TO LEARN MORE ABOUT HOW ADAMAS CAN ASSIST YOU DURING THIS UNPRECEDENTED TIME.

PLEASE CALL US ON **+44 (0)1344 751 210** IN EUROPE,  
**+1-919-341-3361** IN THE US, OR VISIT OUR WEBSITE AT  
**[WWW.ADAMASCONSULTING.COM](http://WWW.ADAMASCONSULTING.COM)**.

# CONDUCT AND REPORTING

- **THE QISA WILL BE CONDUCTED ACCORDING TO THE SCOPE AND WITHIN THE TIMELINES AGREED WITH THE SPONSOR. TOPICS INCLUDE:**
  - Principal Investigator (PI) Oversight
  - Protocol Compliance
  - Informed Consent process
  - Essential Documents
  - Contracts and Agreements
  - Ethics/Regulatory
  - Document Management/Filing/Archiving
  - Personnel and Training
  - Monitoring and Site Management
  - Safety Reporting review/process
  - Source Data Verification
  - Investigational Medicinal Product (IMP)/Investigational Medical Device
  - Laboratory Sample Management
  - Equipment (depending on access to documentation)
  - E-system access/security (as applicable)
  
- **A COMPREHENSIVE QISA REPORT WILL BE PROVIDED WITHIN THE AGREED TIMELINES**



## ADAMAS REMOTE SERVICE OFFERINGS CAN HELP YOU



**MONITOR COMPLIANCE**



**MAINTAIN OVERSIGHT**



**MANAGE RISK**

Is it possible to monitor compliance, maintain oversight and manage risk during the COVID-19 pandemic? ADAMAS have the experience, know-how and tools to provide remote service solutions to meet these challenges.

## MITIGATION AND MANAGEMENT

Regulators have set a clear expectation that compliance and Sponsor oversight are maintained at all times, even if it is not possible to conduct compliance activities on site as would be normal practice.

ADAMAS remote service offerings provide solutions and assurance with credible alternatives.

You can play the video online on our [COVID-19 services page](#).





# SERVICE OFFERINGS

Discover how ADAMAS can provide you with remote compliance solutions.



## QUALITY INVESTIGATOR SITE ASSESSMENT

QISAs allow the evaluation of key aspects covered during an ISA



## VENDOR ASSESSMENTS

Due diligence on behalf of a client in the process of acquiring a new vendor



## MOCK INSPECTIONS

Mock GCP and Pharmacovigilance Inspections conducted remotely to specification



## SOP DEVELOPMENT

GxP SOP Gap Analysis. New and revised SOP creation and review



## QMS CONSULTANCY

Assess the effectiveness of your quality management system





## VISIT OUR BLOG SECTION

Keep up-to-date with the latest news, events and industry insights. Our blogs include:

- [COVID-19 | MITIGATION & MANAGEMENT](#)
- [COVID-19 | REMOTE AUDITING - A VIABLE ALTERNATIVE IN CHALLENGING TIMES](#)
- [COVID-19 | CONDUCTING REMOTE AUDITS](#)
- [COVID-19 | A NOVEL VIRUS NEEDS A NOVEL APPROACH](#)
- [COVID-19 | GUIDANCE ON THE MANAGEMENT OF CLINICAL TRIALS](#)
- [COVID-19 | MAINTAINING INSPECTION READINESS](#)
- [COVID-19 | PHARMACOVIGILANCE UPDATE](#)

## HOW CAN WE HELP

To find out more about what ADAMAS can do to support your audit program during these challenging times, please feel free to call us on **+44 (0)1344 751 210** in Europe, **+1-919-341-3361** in the US; or email us at [info@adamasconsulting.com](mailto:info@adamasconsulting.com).

AMERICAS

EMEA

APAC



## CONTACT DETAILS

Contact us to see how we could help you and to discuss your individual requirements.

### Europe, Middle East & Africa

ADAMAS Consulting Ltd  
Building B, Watchmoor Park  
Riverside Way, Camberley  
Surrey, GU15 3YL  
United Kingdom

Contact

#### Robert Barnes

Business Development Director, EMEA

#### Carly Davenport

Business Development Director

Tel: +44 (0)1344 751 210

info@adamasconsulting.com

### Asia & Pacific

ADAMAS Clinical Quality Consulting Pvt  
White Hall  
Mezzanine Floor 'B'  
143 August Kranti Marg  
Mumbai 400036, India

Contact

#### Shehnaz Vakharia

Vice President, APAC

Tel: +91 (22) 68841501

info@adamasconsulting.com

### USA & Canada, Central & South America

ADAMAS Consulting LLC  
300 Brickstone Square  
Suite 201  
Andover, MA 01810  
United States of America

ADAMAS Consulting LLC  
501 W. Broadway  
Suite 800,  
San Diego, CA 92101  
United States of America

Contact

#### Katherine Kovac

Business Development Manager, Americas

Tel: +1-619-446-6992

info@adamasconsulting.com

### FOLLOW US ON:



@AdamasCQA



/company/adamas-consulting



www.adamasconsulting.com/blog